Osimertinib is the most promising tyrosine‐kinase inhibitor (TKI) to treat T790M‐acquired resistance in patients with non‐small cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) mutation.1 Immune checkpoint inhibitors (ICIs), such as anti‐programmed death‐1 (PD‐1)/anti‐programmed death ligand‐1 (PD‐L1) antibodies, have been identified as therapeutic agents that may influence long‐term prognosis of patients with NSCLC.2 However, combined or sequential use of ICI and EGFR‐TKI is known to potentially increase the risk of known adverse events. Here, CD274 is linked to non-small cell lung carcinoma.